Vicky Stinson, a 65-year-old retired landscape architect from Arizona, was told she had months to live when doctors diagnosed her with Stage 3 pancreatic cancer. Two years later, she's still hiking mountain trails in Italy and Colorado, working with her doctors to extend her survival one month at a time. Her story marks a turning point in one of medicine's most stubborn battles: pancreatic cancer, a disease that has long outpaced treatment advances seen in nearly every other cancer type.
For decades, pancreatic cancer has remained a clinical nightmare. Around 70,000 Americans are diagnosed each year, yet nearly 80% arrive at the clinic already in advanced stages. The five-year survival rate hovers at just 13%—a statistic that reflects both the disease's biology and the pancreas's hidden anatomy. The organ sits deep within the body, tucked behind major organs and blood vessels, making tumors invisible to routine checks. Early symptoms—abdominal pain, weight loss, new-onset diabetes—masquerade as minor ailments, delaying diagnosis by months or even years. Worse, surgical oncologist Rajesh Ramanathan explains that pancreatic tumors create a protective "cocoon" around themselves, blocking chemotherapy from ever reaching cancer cells. Oncologist Arif Kamal describes the disease differently: not as a solid mass but as "scattered grains of sand," impossible to fully contain.
Yet the breakthrough that changed Stinson's trajectory—and potentially thousands of others—arrived with a single pill. In clinical trials published in The New England Journal of Medicine, researchers tested daraxonrasib, an experimental drug belonging to a new class of therapies called RAS inhibitors. Rather than poisoning rapidly dividing cells, daraxonrasib targets the genetic mutations that drive the cancer itself, marking a shift toward personalized medicine. The results were striking: patients using daraxonrasib lived approximately eight to nine months without disease progression, compared to just two to three months under traditional chemotherapy.
For Stinson, the difference was tangible. Unlike chemotherapy infusions that demand hours in treatment centers, daraxonrasib arrived as a pill. Side effects were manageable—mild acne-like symptoms—leaving her energy intact for the things she loved. She hiked. She traveled. She exercised. She lived, not merely endured.
Lead investigator Brian Wolpin sees this shift as potentially transformational. By targeting the genetic drivers of disease rather than attacking all rapidly dividing cells indiscriminately, pancreatic cancer treatment can finally move beyond one-size-fits-all chemotherapy toward medicine tailored to each patient's unique cancer biology. This mirrors breakthroughs that have already revolutionized care for breast cancer, lung cancer, and melanoma through immunotherapy, AI imaging, and precision genetic testing—advances that had seemed out of reach for pancreatic cancer until now.
Stinson's participation in the daraxonrasib trial extended her survival and fundamentally changed how she experienced living with her diagnosis. She became not just a patient but an advocate, supporting research efforts while proving that new pancreatic cancer drugs are beginning to deliver something the disease has long denied: hope measured not in years but in everyday moments—a hike through the Rockies, a trip to Europe, the time to watch your loved ones thrive.